Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, South Australia, Australia.
Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1484-1492. doi: 10.2215/CJN.03200319. Epub 2019 Aug 27.
The burden of infectious disease is high among kidney transplant recipients because of concomitant immunosuppression. In this study the incidence of infectious-related mortality and associated factors were evaluated.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this registry-based retrospective, longitudinal cohort study, recipients of a first kidney transplant in Australia and New Zealand between 1997 and 2015 were included. Cumulative incidence of infectious-related mortality was estimated using competing risk regression (using noninfectious mortality as a competing risk event), and compared with age-matched, populated-based data using standardized incidence ratios.
Among 12,519 patients, (median age 46 years, 63% men, 15% diabetic, 6% Indigenous ethnicity), 2197 (18%) died, of whom 416 (19%) died from infection. The incidence of infection-related mortality during the study period (1997-2015) was 45.8 (95% confidence interval [95% CI], 41.6 to 50.4) per 10,000 patient-years. The incidence of infection-related mortality reduced from 53.1 (95% CI, 45.0 to 62.5) per 10,000 person-years in 1997-2000 to 43.9 (95% CI, 32.5 to 59.1) per 10,000 person-years in 2011-2015 (<0.001) Compared with the age-matched general population, kidney transplant recipients had a markedly higher risk of infectious-related death (standardized incidence ratio, 7.8; 95% CI, 7.1 to 8.6). Infectious mortality was associated with older age (≥60 years adjusted subdistribution hazard ratio [SHR], 4.16; 95% CI, 2.15 to 8.05; reference 20-30 years), female sex (SHR, 1.62; 95% CI, 1.19 to 2.29), Indigenous ethnicity (SHR, 2.87; 95% CI, 1.84 to 4.46; reference white), earlier transplant era (2011-2015: SHR, 0.39; 95% CI, 0.20 to 0.76; reference 1997-2000), and use of T cell-depleting therapy (SHR, 2.43; 95% CI, 1.36 to 4.33). Live donor transplantation was associated with lower risk of infection-related mortality (SHR, 0.53; 95% CI, 0.37 to 0.76).
Infection-related mortality in kidney transplant recipients is significantly higher than the general population, but has reduced over time. Risk factors include older age, female sex, Indigenous ethnicity, T cell-depleting therapy, and deceased donor transplantation.
This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_08_27_CJN03200319.mp3.
由于同时接受免疫抑制治疗,肾移植受者的传染病负担很高。本研究评估了感染相关死亡率及其相关因素。
设计、地点、参与者和测量:本研究采用基于注册的回顾性、纵向队列研究,纳入了 1997 年至 2015 年间在澳大利亚和新西兰接受首次肾移植的患者。使用竞争风险回归估计感染相关死亡率的累积发生率(以非感染性死亡率为竞争风险事件),并使用标准化发病率比与年龄匹配的人群数据进行比较。
在 12519 例患者中(中位年龄 46 岁,63%为男性,15%患有糖尿病,6%为土著居民),2197 例(18%)死亡,其中 416 例(19%)死于感染。研究期间(1997-2015 年)感染相关死亡率的发生率为 45.8(95%置信区间[95%CI],41.6 至 50.4)/10000 患者年。感染相关死亡率从 1997-2000 年的 53.1(95%CI,45.0 至 62.5)/10000 患者年降至 2011-2015 年的 43.9(95%CI,32.5 至 59.1)/10000 患者年(<0.001)。与年龄匹配的一般人群相比,肾移植受者感染相关死亡的风险明显更高(标准化发病率比,7.8;95%CI,7.1 至 8.6)。感染性死亡率与年龄较大(≥60 岁,调整后的亚分布风险比[SHR],4.16;95%CI,2.15 至 8.05;参考年龄 20-30 岁)、女性(SHR,1.62;95%CI,1.19 至 2.29)、土著居民(SHR,2.87;95%CI,1.84 至 4.46;参考白人)、较早的移植时代(2011-2015 年:SHR,0.39;95%CI,0.20 至 0.76;参考 1997-2000 年)和使用 T 细胞耗竭治疗(SHR,2.43;95%CI,1.36 至 4.33)相关。活体供者移植与较低的感染相关死亡率风险相关(SHR,0.53;95%CI,0.37 至 0.76)。
肾移植受者的感染相关死亡率明显高于一般人群,但随着时间的推移有所下降。危险因素包括年龄较大、女性、土著居民、T 细胞耗竭治疗和已故供者移植。